Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 71

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 71
---
. (Nasdaq:TELO).

Approvals

The Board of Directors of SKNY has unanimously approved the Merger Agreement and recommends that shareholders of SKNY approve the Merger. Similarly, the Board of Directors of MIRA has approved the Merger and recommends that its shareholders vote “FOR” the issuance of shares in connection with the Merger.

Termination

The Merger Agreement provides for termination under certain circumstances, including:

| ● 
 ● 
 ● | Mutual                                                                       
 written consent of MIRA and SKNY                                             
 Failure                                                                      
 to obtain shareholder approval by MIRA and by SKNY;                          
 If                                                                           
 the Closing has not occurred by December 31, 2025;                           |
|:--|:-----------------------------------------------------------------------------|
| ● | If                                                                           
 a Governmental Entity has issued a final ruling prohibiting the Closing; and |
| ● | By                                                                           
 one party upon an uncured breach of the Merger Agreement by the other party. |

Treatment of SKNY Stock Options

SKNY currently has no stock options outstanding.

Treatment of SKNY Warrants

Under the terms of the Merger Agreement, each warrant to purchase shares of SKNY Common Stock that is outstanding will be converted into and become a warrant to purchase shares of MIRA Common Stock and MIRA will assume each SKNY warrant in accordance with its terms.

Treatment of MIRA Options, RSUs and Warrants

MIRA’s outstanding options, RSUs and warrants will not be affected by the Merger.

Representations and Warranties

The Merger Agreement contains representations and warranties that MIRA and Merger Sub, on the one hand, and SKNY, on the other hand, have made to one another as of specific dates. These representations and warranties have been made for the benefit of the other parties to the Merger Agreement and may be intended not as statements of fact but rather as a way of allocating the risk to one of the parties if such statements made in the representations and warranties prove to be incorrect. In addition, the assertions made in the representations and warranties are qualified by the information in confidential disclosure schedules exchanged by the parties in connection with the signing of the Merger Agreement. While MIRA and SKNY do not believe that these disclosure schedules contain information required to be publicly disclosed under the applicable securities laws, other than information that has already been so disclosed, the disclosure schedules contain information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the Merger Agreement. Accordingly, you should not rely on the representations and